Faruqi & Faruqi Investigates Intellia Therapeutics for Potential Securities Violations Following NASDAQ:NTLA's Recent Stock Price Decline

Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Deadline of April 25, 2025

NEW YORK, April 24, 2025 /PRNewswire/ -- Faruqi & Faruqi, a leading national securities law firm, reminds investors of Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of the pending class action lawsuit.

The lawsuit was filed in the United States District Court for the Southern District of New York and is captioned "Santos v. Intellia Therapeutics, Inc., et al., Case No. 22-cv-01234." The lawsuit alleges that the Company and certain of its officers and directors made false and/or misleading statements and/or failed to disclose material information to the public during the class period, which began on April 25, 2022, and ended on July 12, 2022.

On July 12, 2022, the Company announced that it would be delaying its anticipated regulatory submission for its lead product candidate, NTLA-200, to the end of 2022. The news caused the Company's stock price to drop significantly, damaging investors.

The lawsuit seeks to recover damages on behalf of all Intellia investors who purchased or acquired the Company's securities during the class period. The deadline to file a motion to join the lawsuit is April 25, 2025.

Investors who purchased or acquired Intellia securities during the class period and have suffered a loss are encouraged to contact Faruqi & Faruqi's office at (212) 983-9331 or [email protected] to discuss their potential legal remedies.

Faruqi & Faruqi is a leading national securities law firm with experienced attorneys who have a track record of success in recovering losses on behalf of shareholders. The firm's attorneys have extensive experience in the prosecution of class actions and have recovered hundreds of millions of dollars on behalf of investors.

Contact: Faruqi & Faruqi (212) 983-9331 [email protected]